Primary mediastinal B-cell lymphoma: detection of BCL2 gene rearrangements by PCR analysis and FISH by Dunphy, Cherie H. et al.
ORIGINAL ARTICLE
Primary mediastinal B-cell lymphoma: detection of BCL2
gene rearrangements by PCR analysis and FISH
Cherie H. Dunphy & Dennis P. O’Malley & Liang Cheng &
Tina Y. Fodrie & Sherrie L. Perkins &
Kathleen Kaiser-Rogers
Received: 29 January 2008 /Accepted: 24 April 2008 /Published online: 18 June 2008
# Springer-Verlag 2008
Abstract Primary mediastinal large B-cell lymphoma
(PMBCL) has a characteristic clinical presentation, mor-
phology, and immunophenotype, representing a clinically
favorable subgroup of diffuse large B-cell lymphoma
(DLBCL). By gene expression profiling (GEP), PMBCL
shares features with classical Hodgkin lymphoma (cHL).
Of further interest, BCL6 gene mutations and BCL6 and/or
MUM1 expression in a number of PMBCLs have supported
an activated B-cell (ABC) origin. Several studies, including
GEP, have failed to detect BCL2 gene rearrangements
(GRs) in PMBCL. An index case of t(14; 18)+ PMBCL
prompted our study of the incidence of BCL2 GRs in
PMBCL by polymerase chain reaction (PCR)/fluorescence
in situ hybridization (FISH) analyses and its possible
clinical impact. Twenty-five retrospectively identified,
well-defined PMBCLs (five with cytogenetics) from three
institutions were analyzed for a BCL2 GR by PCR/FISH
analyses. The formalin-fixed, paraffin-embedded tissue
blocks of 24 available cases were also analyzed by BCL2
immunohistochemistry (IHC). Of the five with cytogenet-
ics, two had a t(14; 18) (q32; q21). Of the 25 analyzed by
PCR, 2 had no amplifiable DNA (aDNA), including 1 t(14;
18)+ case. Of those with aDNA, two showed a BCL2 GR;
by FISH analysis, three demonstrated a BCL2 GR. BCL2
protein expression by IHC analysis was variably detected in
21 out of 24 (strongly, uniformly expressed: 6, including all
with a t(14; 18) or a BCL2 gene rearrangement; moderately
weakly expressed in a subset of the malignant cells: 15).
Available clinical follow-up of this BCL2+ subset showed a
similar course to the other PMBCL cases. Our results imply
that a subset of PMBCL [(4 out of 24 analyzed) in our
series] may be of GC origin. A larger study is necessary to
determine any clinical significance.
Keywords PrimarymediastinalB-celllymphoma.BCL2
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Introduction
Primary mediastinal B-cell lymphoma (PMBCL) is a
diffuse large B-cell lymphoma (DLBCL) first described in
1981 and postulated to arise from noncirculating thymic B
lymphocytes [1, 2]. It is recognized as a distinct entity
within the World Health Organization (WHO) classification
of lymphomas and represents a clinically favorable sub-
group of DLBCL [i.e., better 5-year survival rate (64%),
than all DLBCLs after therapy (46%)] [3, 4]. It is
characterized by a distinctive clinical presentation, mor-
phology, and immunophenotype. Interestingly, by gene-
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e-mail: cdunphy@unch.unc.eduexpression profiling, PMBCL shares features with classical
Hodgkin lymphoma [4, 5]. Of further interest, BCL6 gene
mutations and BCL6 and/or MUM1 expression in a number
of PMBCLs have supported an activated (or post-germinal
center) B-cell (ABC) origin [6]. In addition, several studies,
including gene-expression profiling, have failed to detect
BCL2 gene rearrangements in PMBCL [7–9]. An index
case of PMBCL associated with a t(14; 18) prompted our
study of the incidence of BCL2 gene rearrangements in
PMBCL by polymerase chain reaction (PCR) analysis and
fluorescent in situ hybridization (FISH) and its possible
clinical impact.
Materials and methods
Retrieval of case and clinical follow-ups
Twenty-five consecutive cases, meeting the WHO criteria
(definition and description) for a diagnosis of PMBCL
(provided below) [3], were retrospectively identified from
the three participating academic institutions. The WHO
definition and description for PMBCL is stated as follows
“a subtype of DLBCL arising in the mediastinum of putative
B-cell origin with distinctive clinical, immunophenotypic, and
genotypic features. Patients present with localized disease and
signs and symptoms relating to large anterior mediastinal
masses, sometimes with impending superior vena cava
syndrome. When disseminated, other extranodal sites are
often involved, such as kidney, liver, skin and brain. The
neoplastic cells vary in size and shape. In most cases, the cells
have abundant cytoplasm.” There is often associated fibrosis
in the background. The cells typically express CD19 and
CD20, and often lack surface light chain expression by flow
cytometry. They may weakly express CD30, either focally or
extensively. CD10 and CD5 are absent. The available clinical
data regarding presentation, bone marrow staging, and
therapeutic follow-up, as well as histologic sections, flow
cytometric immunophenotypic data, immunohistochemical
immunophenotypic data, and conventional cytogenetic results
(available in five cases) were reviewed, and the results
supported a diagnosis of PMBCL in each of these cases.
Retrospective analysis of BCL-2 rearrangement
by polymerase chain reaction
Tissue samples from 25 patients were qualitatively analyzed
for a BCL2 rearrangement, using a nested PCR assay and
gel electrophoresis. Formalin-fixed paraffin-embedded tis-
sue was digested in a proteinase K digestion buffer for 24 h
at 56°C and then purified using the QIAamp DNA Mini Kit
according to manufacturer’s instructions (QIAGEN, Valen-
cia, CA, USA).
A nested PCR assay was performed using a BCL2
rearrangement assay kit manufactured by InVivoScribe
Technologies (San Diego, CA, USA). It involves two
nested PCRs, using four sets of primers that target the
joining region of the immunoglobulin heavy chain gene and
distinct regions of the BCL2 gene. Two sets of primers were
used to identify BCL2 rearrangements, involving the major
breakpoint (Mbr). The second two sets of primers target the
minor cluster region (Mcr). The limit of detection, using
nested amplifications, is less than one BCL2-rearrangement
positive cell in ten thousand normal cells (limit of detection
<10
−4). An additional set of primers targeted a HLA class II
gene to ensure that the quality and quantity of DNA present
was sufficient to generate a valid result. A genomic
sequence (Factor V) was also amplified and detected to
serve as an additional amplification control for this assay.
All PCR reactions were amplified on the GeneAmp PCR
System 9700 (Applied Biosystems).
Gel electrophoresis was performed on a 2% agarose gel
for 180 min at 70 volts. A DNA size marker (HAE 20 cut
p1598, Sigma-Aldrich, St. Louis, MO, USA) was used to
determine the presence of the 215-bp product formed when
the BCL2 rearrangement was detected in the major break-
point region. A 1,000-bp product formation indicated the
presence of the BCL2 rearrangement in the minor cluster
region. The absence of the 215- or 1,000-bp product
indicated the absence of the BCL2 rearrangement in the
sample. Both positive and polyclonal controls for BCL2
were analyzed in conjunction with the tissue samples. A
“no DNA” control was included as well to ensure the
sterility of PCR reagents. Positive and polyclonal controls
were included in the BCL2 rearrangement assay kit
provided by InVivoscribe Technologies. Because by a
nested PCR assay, rare cells may be detected that carry
BCL2 translocations, all cases positive for a BCL2
translocation were confirmed, as described below, by FISH
analysis.
Retrospective analysis of BCL-2 rearrangement
by fluorescent in situ hybridization
Fluorescence in situ hybridization (FISH) was performed
on 24 paraffin embedded samples using Vysis’ BCL2 dual
color, break apart probe (Abbott Molecular/Vysis Inc., Des
Plaines, IL, USA) according to the manufacturer's protocol.
For each paraffin-embedded sample, an adjacent hematox-
ylin- and eosin-stained section was evaluated by an
experienced pathologist, and the tumor was marked before
FISH analysis. Each FISH slide was scored in a blinded
fashion by two independent individuals. For those samples
demonstrating a clearly abnormal fluorescence pattern
(>20% abnormal cells), consistent with rearrangement of
the BCL2 gene, at least 100 cells were examined. For those
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with the presence of an intact BCL2 gene (<10% abnormal
cells), at least 200 cells were examined. The cutoff values
used for the BCL2 assay were based on our databases for
multiple break apart probes, as well as our experience with
paraffin samples. In addition, the BCL2 break apart assay
was performed on three known abnormal [three follicular
lymphomas with a t(14; 18) by routine cytogenetic studies]
and six normal paraffin-embedded control samples (all,
reactive follicular hyperplasia) in conjunction with this
study.
Retrospective immunohistochemical analysis
The formalin-fixed, paraffin-embedded tissue blocks of 24
available cases were also analyzed by BCL2 immunohisto-
chemistry (LSAB2 kit, Dako Corporation, Carpinteria, CA,
USA; 1:10 dilution; antigen retrieval: 6.0 pH citrate buffer–
steam for 30 min) to determine correlation of a BCL2
rearrangement with BCL2 protein expression. These blocks
were also analyzed by immunohistochemistry for expres-
sions of CD10 (clone 56C6, predilute, Neomarkers,
Fremont, CA, USA; antigen retrieval: 10.0 pH citrate
buffer–steam for 30 min), BCL6 (clone 4242, Cell
Signalling, Danvers, MA, USA; 1:20 dilution; antigen
retrieval: 10.0 pH citrate buffer–steam for 30 min),
MUM1 (clone MUM1p, Dakocytomation, Carpinteria,
CA, USA; 1:50 dilution; antigen retrieval: 6.0 pH citrate
buffer–steam for 30 min) and CD138 (CD138/Syndecan-1,
Cell Marque, Hot Springs, AR, USA). All of these markers
were analyzed by an automated staining and detection
system (BenchMark XT, Ventana Medical Systems, Phoe-
nix, AZ, USA), if not performed at the time of initial
diagnosis. Cases were classified into three expression
patterns: (1) a germinal center (GC) B-cell pattern (express-
ing CD10 and/or BCL6 but not activation markers: CD138
and MUM1); (2) an activated GC B-cell pattern (expressing
at least one of the GC B-cell markers and one of the
activation markers); and (3) an activated (post-germinal
center) B-cell (ABC) pattern (expressing MUM1 and/or
CD138 but not germinal center B-cell markers) [9].
Results
Retrieval of cases
Twenty-five cases retrospectively reviewed from the three
perspective academic institutions met the stated general
WHO criteria for a diagnosis of PMBCL (Table 1). The
patients ranged from 15 to 83 years of age with a female is
to male ratio of 1.4:1.0. All patients presented with a
primary, large anterior mediastinal mass, and 21 out of 25
initial diagnoses were based on a mediastinal biopsy. The
other four diagnostic biopsies originated from supraclavic-
ular lymph nodes (two cases), thoracic lymph nodes (one
case), or a lung biopsy (one case). No other sites of
lymphomatous involvement were identified, and all staging
bone marrows were negative for lymphomatous involve-
ment. All had the typical morphology of PMBCL,
characterized by a massive, diffuse proliferation of variably
sized cells associated with abundant, pale cytoplasm and
variably dense compartmentalizing fibrosis (Fig. 1). Of the
11 cases with available flow cytometric immunophenotypic
data, 4 demonstrated lack of any surface light chain
expression, which frequently occurs in PMBCL. Of the 23
cases with available immunohistochemical immunopheno-
typic data at the time of original diagnosis, all were CD45-
and CD20-positive. CD30 was expressed in 13 out of 16
analyzed cases, as is also frequently observed in PMBCL.
CD30 was expressed in one of the cases with a BCL2
rearrangement, was negative in one of the cases with a
BCL2 rearrangement, and was not performed in the two
remaining cases with a BCL2 rearrangement. CD10 was not
expressed in the majority of cases (18 out of 24); it was
weakly to moderately expressed in the remaining cases,
only 2 of which had a BCL2 rearrangement. Although
CD10 is stated as being absent in the WHO description of
PMBCL, CD10 expression does not exclude a diagnosis of
PMBCL. In addition, the two cases with a t(14; 18) by
conventional cytogenetic studies were CD10-negative.
CD23 was expressed in five of six cases tested. The
CD23-negative case was not associated with a BCL2
rearrangement. Two of the 5 CD23+ cases were associated
with a BCL2 rearrangement. Of the five cases with
conventional cytogenetic results, two revealed a t(14; 18)
(q32; q21). Both of these cases were associated with
additional abnormalities. The other three cases showed
abnormalities as depicted in Table 1. Two of these three
cases revealed abnormalities that have been frequently
described in PMBCL (i.e., abnormalities of 9p and 6p).
Retrospective analysis of BCL2 rearrangement by PCR
Of 25 cases studied, 2 did not yield amplifiable DNA
[including 1 case with a t(14; 18) by conventional
cytogenetic studies]. Of the 23 cases with amplifiable
DNA, a BCL2 gene rearrangement was detected in 2 cases
(Fig. 2). These two cases had not had conventional
cytogenetic studies performed.
Retrospective analysis of BCL2 rearrangement by FISH
Nineteen of the 24 analyzed paraffin-embedded samples
demonstrated no evidence of a BCL2 rearrangement; the
mean number of cells with a relevant abnormal signal
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data did not differ significantly from the six normal control
specimens assayed with the BCL2 break-apart probe. The
three remaining samples did reveal evidence of a BCL2
rearrangement. In one abnormal sample (case no. 16), 66%
of the approximate 100 interphase cells examined demon-
strated a fluorescence pattern consistent with a rearrange-
ment involving BCL2; in the second abnormal sample (case
no. 18), 89% of the cells examined demonstrated a BCL2
rearrangement; and in the third abnormal sample (case no.
25), 86% of the cells examined demonstrated a BCL2
rearrangement (Fig. 3). Of note, this third abnormal sample
did not reveal a BCL2 gene rearrangement by PCR analysis.
Despite several attempts, sufficient probe hybridization for
analysis was not able to be obtained from two samples
[including the case with a t(14; 18) by conventional
Table 1 PMBCL cases with cytogenetic, molecular, and immunohistochemical data
Case no. Age Sex Flow Conv cytogen PCR
bcl-2
FISH
bcl-2
IHC bcl-2 IP (GC, AGC, ABC)
a
1 42 M NP 83–90 tetra ,−Y, +X,
+X dup1q, −1 der/
re9p&11p
Neg Neg bcl-2 – ABC (MUM1+)
2 53 F NP NP Neg Neg bcl-2 +++ ABC (MUM1+)
3 83 F MBC 90–91 tetra num abn incl
2 copies of t(14; 18)
NADNA NR bcl-2 +++ GC (BCL6+)
4 31 F NP NP Neg Neg bcl-2 ++ AGC (MUM1+, BCL6+)
5 41 M NP NP Neg Neg bcl-2+++ AGC (MUM1+, BCL6+)
6 56 F MBC t(1; 4), t(5; 8) add 6p,
ring
Neg Neg bcl-2 v+ (s) AGC (MUM1+, BCL6+)
7 24 F BC with loss of
lt ch exp
del 1p, −Y, −15 t(2; 5)
(q21; q13.3)
NADNA NR bcl-2 v+ (s) NA
8 35 F NR NR Neg Neg bcl-2 v+ (s) AGC (MUM1+, BCL6+,
CD10+)
9 44 M NR NR Neg Neg bcl-2 v+ (s) AGC (MUM1+, BCL6+)
10 24 M NP NP Neg Neg bcl-2 v+ (s) NR
11 23 M NP NP Neg NA NA AGC (MUM1+, BCL6+)
12 30 F NP NP Neg Neg bcl-2 v+ (s) AGC (MUM1+, BCL6+)
13 25 F MBC NP Neg Neg bcl-2 v+ (s) AGC (MUM1+, BCL6+,
CD10+)
14 23 M MBC with wk
CD10 (s)
NP Neg Neg bcl-2 – AGC (MUM1+, BCL6+)
15 41 M BC with loss of
lt ch exp
NP Neg Neg bcl-2 v+ (s) ABC (MUM1+)
16 65 F MBC with
CD10 +
NP Pos Pos bcl-2 +++ AGC (MUM1+, BCL6+)
17 37 M NR NP Neg Neg bcl-2 v+ (s) AGC (MUM1+, BCL6+)
18 76 F BC with loss of
lt ch exp
NP Pos Pos bcl-2 v+ AGC (MUM1+, BCL6+,
CD10+)
19 20 M MBC CD22+
CD11c+
NP Neg Neg bcl-2 v+ (s) ABC (MUM1+)
20 24 M MBC CD22+ NP Neg Neg bcl-2 v+ (s) AGC (MUM1+, BCL6+,
CD10+)
21 15 F NR NP Neg Neg bcl-2 v+ (s) AGC (MUM1+, BCL6+)
22 39 F NR NP Neg Neg bcl-2 – ABC (MUM1+)
23 34 M NR NP Neg Neg bcl-2 v+ (s) ABC (MUM1+)
24 28 F NP NP Neg Neg bcl-2 v+ (s) ABC (MUM1+)
25 65 F BC with loss of lt
ch exp CD10-
Multiple abns with
t(14; 18)
Neg Pos BCl-2+++ GC (BCL6+)
Conv cytogen Conventional cytogenetics, PCR polymerase chain reaction, FISH fluorescent in situ hybridization, IHC immunohistochemical, IP
immunophenotype, GC germinal center, AGC activated germinal center, ABC activated B- (post-germinal center) cell, NP not performed, MBC
monoclonal B cells, NADNA no amplifiable DNA, NR no results, BC B cells, lt ch exp light chain expression, NA not available, abns
abnormalities, v+ variably positive, (s) subset
aIndicates only positive markers are listed
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analysis]. Of note, a number of the samples demonstrated
one to three extra intact BCL2 signals in a significant
portion of the examined cells, suggesting the presence of
polysomy 18 and/or a partial aneuploidy involving this
locus.
Retrospective IHC analysis
Of the 24 cases analyzed by BCL2 immunohistochemistry,
BCL2 protein expression was variably detected in 21 cases
(strongly and uniformly expressed in 6 cases, including the
4w i t hat(14; 18) or a BCL2 gene rearrangement, and
moderately to weakly expressed in a subset of the
malignant cells in the remaining 15 cases). The immuno-
histochemical analysis of the 23 available cases with CD10,
BCL6, CD138, and MUM1 revealed a germinal center
(GC) immunophenotype in 2 cases [1 with t(14; 18) by
conventional cytogenetics and 1 with t(14; 18) by conven-
tional cytogenetics and FISH alone], an activated GC
immunophenotype in 14 cases (the remaining 2 cases with
BCL2 gene rearrangements detected by PCR and FISH) and
an activated B-cell (ABC) immunophenotype in the
remaining 7 cases, as defined by Chang et al. [10].
Fig. 2 This image demonstrates the presence of a bcl-2 gene
rearrangement in cases nos.18 and 16 compared to the positive control
(PC) by PCR analysis. Note the first column represents patient no. 18;
the second column, patient no. 11; the third column, patient no. 16; the
fourth column, patient no. 12; the fifth column, a PC; the sixth
column, a normal polyclonal sample; and the seventh column, a
sample with no DNA. The lower bands in the columns of case nos. 11
and 12 are not of the appropriate size for interpretation
Fig. 3 This image demonstrates fluorescence in situ hybridization
results of case no. 25. Shown is interruption of the BCL2 locus in the
paraffin-embedded tissue section. The large arrowed cell in the center
contains four fusion signals (yellow or overlapped red and green
signals) representing four intact BCL2 loci. Interruption of one BCL2
locus is evidenced by the single red (telomeric or 5′ flanking region)
and green (centromeric or 3′ flanking region) signals in this cell. Each
of the other cells in the field also contains individual red and/or green
signals reflecting interruption of the BCL2 locus
Fig. 1 Sections of the cervical lymph node in this patient with a large
anterior mediastinal mass reveal the evident background of fibrosis
between the malignant cells (a ×400, hematoxylin–eosin stain) that are
variable in size with abundant, pale cytoplasm (b ×400, hematoxylin–
eosin stain)
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The treatment and clinical follow-up of all available cases
(21 of 25 cases) are provided in Table 2. One case with a
BCL2 gene rearrangement by PCR and/or FISH and an
activated GC immunophenotype (case no. 18) had a good
response to conventional chemotherapy with or without
radiotherapy and was in complete remission at last follow-
up (2 years after initial diagnosis and subsequent therapy).
The case with a t(14; 18) by conventional cytogenetic
studies and a GC immunophenotype (and no amplifiable
DNA by PCR analysis and insufficient probe hybridization
by FISH analysis) experienced two recurrences within
2.5 years of initial diagnosis, despite CHOP-Rituxan
chemotherapy and consolidative radiotherapy. The case
with a BCL2 gene rearrangement detected by PCR and an
AGC immunophenotype (case no. 16) experienced a late
relapse in the mediastinum, supraclavicular lymph nodes,
and lung and died of disease within 1.5 years. The fourth
patient with a t(14; 18) by conventional cytogenetic studies
and a BCL2 gene rearrangement by FISH (case #25) had no
available clinical follow-up. In comparison to the PMBCL
cases without a t(14; 18) or a BCL2 gene rearrangement,
there does not appear to be any significant difference in
outcome, as there were also relapses and one patient died of
disease within 2 years in this group.
Table 2 Correlation of molecular and cytogenetic data with treatment and follow-up
Case no. Conv cytogen PCR bcl-2 FISH bcl-2 Treatment and follow-up
18 3 –90 tetra, −Y, +X, +X dup1q,
−1 der/re9p&11p
Neg Neg CHOP and XRT; CR; 6 years
2 NP Neg Neg R-CHOP and XRT; CR; 5 years
39 0 –91 tetra num abn incl 2
copies of t(14; 18)
NADNA NR R-CHOP in CR at 1 year; recurred in right eye at 2 years
4 NP Neg Neg CHOP and XRT; CR; 5 years
5 NP NEG Neg R-CHOP; CR; 4 years
6 t(1; 4), t(5; 8) add 6p, ring Neg Neg R-CHOP; CR at 1 year; relapsed within 3 years; treated
with 2 cycles R-ICE, BEAM chemotx, auto SCT; CR 1 year out
7 del 1p, −Y, −15 t(2; 5) (q21;
q13.3)
NADNA NR R-CHOP; CR; 4 years
8 NR Neg Neg R-CHOP; CR; 3 years
9 NR Neg Neg No follow-up available
10 NP Neg Neg CHOP and XRT; CR; 7.5 years
11 NP Neg NA CHOP and XRT; CR; 6 years
12 NP Neg Neg R-CHOP and XRT; CR; Developed recurrence supraclavicular LN
9 months after tx; received ABMT; CR 3 years after transplant
13 NP Neg Neg R-CHOP and XRT; CR; 4 years
14 NP Neg Neg R-CHOP and XRT; CR; 3 years
15 NP Neg Neg R-CHOP and XRT; CR; local mediastinal relapse at 6 months;
treated with ABMT; CR; 2.5 years
16 NP Pos Pos R-CHOP; CR; late relapsed in mediastinum, supraclav nodes,
lung; DOD 1.5 years
17 NP Neg Neg R-CHOP and XRT; CR; 2.5 years
18 NP Pos Pos R-CHOP and XRT; CR; 2 years
19 NP Neg Neg CHOP; brain mets treated with Decadron; MTX followed
by Vincristine and then Leucovorin; Liver mets treated
with ESHAP CR; 5 years
20 NP Neg Neg CHOP and XRT; Rituxan DEPA; at 1 year last follow-up;
pulmonary nodules causing at least 50% opacification of
thorax; no additional follow-up
21 NP Neg Neg COPADM1, M2, and CYM1; 5961C chemotx and XRT;
Rituxan relapse and DOD within 2 years
22 NP Neg Neg R-CHOP; CR at 5 years
23 NP Neg Neg No follow-up available
24 NP Neg Neg No follow-up available
25 Multiple abns with t(14; 18) Neg Pos No follow-up available
CR Complete remission, XRT radiation therapy, R Rituxan, ABMT autologous bone marrow transplant, DOD dead of disease
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Primary mediastinal B-cell lymphoma is defined by the
WHO classification as a primary large anterior mediastinal
mass diffusely infiltrated by variably sized lymphoid cells
with abundant, pale cytoplasm associated with compart-
mentalizing fibrosis. The cells have a B-cell immunophe-
notype frequently associated with lack of surface light
chain expression by flow cytometric immunophenotypic
analysis and with variable expression of CD30 by immu-
nohistochemical analysis. Our 25 retrospectively identified
cases met the WHO criteria based on clinical presentation,
morphology, and immunophenotyping.
As mentioned previously, PMBCL has been postulated
to arise from thymic B cells. This postulation has been
supported, based on expression of MAL. MAL mRNA was
initially identified by a differential screening approach
during the search for T-cell maturation-associated cDNAs
and has been shown to be associated with the intermediate
and later stages of intrathymic T-cell differentiation [11].
Subsequently and interestingly, MAL was shown to be a
distinct molecular marker of PMBCL, being demonstrated
in 70% of PMBCLs and in only 3% of nonmediastinal
DLBCLs, in a study by Copie-Bergman, et al. [12].
Cytogenetic abnormalities that have been described
previously in PMBCLs have included frequent observations
of genetic gains involving chromosomes 2, 5, 7, 9p, 12, and
Xq as well as characteristic abnormalities of 9p in 50% of
cases and alterations of chromosome 6q [13–15]. More
recently, rare cases of PMBCL with t(14; 18) have been
described [16]. In our five cases that were analyzed by
conventional cytogenetic studies, the three cases that were
not associated with a t(14; 18) did reveal a derivative and
rearrangement involving chromosome 9p (1 case) and an
add chromosome (6p; one case).
Although postulated to be of thymic B-cell origin, only
relatively recently has there been molecular characterization
of PMBCL. In 1996, Tsang et al. analyzed molecular
alterations involving BCL1, BCL2, BCL6, c-myc, H-ras, K-
ras, N-ras, and p53 genes and for Epstein–Barr virus (EBV)
infection in PMBCL [8]. Alterations of BCL1, BCL2, or ras
genes and evidence of EBV infection were not observed;
rearrangement of the BCL6 gene was detected in only one
case (16% of cases analyzed).
However, a subsequent molecular study by Pileri et al.
demonstrated that more than half of 40 PMBCLs studied
displayed BCL6 gene mutations, usually occurring together
with functioning somatic IgV(H) gene mutations, and
BCL6 and/or MUM1/IRF4 expression [13]. These findings
suggested derivation of PMBCL from either activated GC
or activated (post-germinal center) B-cells, as CD10 and/or
BCL6, but not activation markers (i.e., CD138 and
MUM1), are expressed in a GC pattern, CD10 or BCL6
and CD138 or MUM1 are expressed in an activated GC
pattern, and CD138 and/or MUM1, but not CD10 or BCL6,
are expressed in the activated (or post-germinal center) B-
cell (ABC) pattern [10]. However, as mentioned previously,
PMBCL is associated with a better prognosis than non-
mediastinal DLBCLs, and of interest, it has been demon-
s t r a t e dt h a tD L B C L sw i t ha na c t i v a t e dG Co rA B C
immunophenotype have worst overall survival and event-
free survival than DLBCLs with a GC immunophenotype
[10, 17].
Gene-expression profiling studies of PMBCL have in
fact supported a strong relationship between PMBCL and
classical Hodgkin lymphoma [4, 5]. Over one third of the
genes that were more highly expressed in PMBCL than in
other DLBCLs were also characteristically expressed in
classical Hodgkin lymphoma cells. These studies identi-
fied a molecular link between PMBCL and classical
Hodgkin lymphoma and a shared survival pathway. Of
interest, these gene expression profiling studies identified
PMBCL as a clinically favorable subgroup, when com-
pared with GC-like DLBCL and ABC-like DLBCL. Of
interest, the PMBCL subgroup was somewhat more
related to the GC-like subgroup of DLBCL, than to the
ABC-like subgroup of DLBCL, even though PMBCL was
clearly distinguishable from both subgroups of DLBCL.
Interestingly, BCL2 gene rearrangements were not de-
scribed in the gene expression profiling studies of
PMBCL.
Our encounter with a case of PMBCL, defined by WHO
criteria, associated with a t(14; 18) prompted our study of
the incidence of this rearrangement by PCR analysis and
FISH analysis in this entity. Although our index case did
not have amplifiable DNA by PCR analysis and did not
have sufficient probe hybridization for FISH analysis, 3 of
23 additional cases of PMBCL with results by PCR and
FISH analyses revealed a BCL2 gene rearrangement by
PCR and FISH (2 cases) and by FISH alone (1 case,
possibly due to sampling differences, or a different
sensitivity by the PCR analysis).
Although our subset of cases with a BCL2 gene
rearrangement may possibly represent non-PMBCL of
follicular origin, closely mimicking the clinical and mor-
phologic features of PMBCL, our results also may imply
that a subset (4 out of 24) of PMBCL in our series may
actually be of GC origin. In particular, two of our cases
[those with t(14; 18) by conventional cytogenetics and or
FISH alone) revealed a GC immunophenotype by immu-
nohistochemical staining. Available clinical follow-up of
this subset showed a similar course to the other PMBCL
cases. A larger study is necessary to determine a significant
clinical impact in this subset. In addition, gene expression
profiling of this subset would be interesting to compare to
PMBCLs of ABC origin.
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